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Anthraquinones are a class of aromatic compounds with a 9,10-dioxoanthracene core. So far, 79 naturally occurring anthraquinones
have been identified which include emodin, physcion, cascarin, catenarin, and rhein. A large body of literature has demonstrated
that the naturally occurring anthraquinones possess a broad spectrum of bioactivities, such as cathartic, anticancer, anti-
inflammatory, antimicrobial, diuretic, vasorelaxing, and phytoestrogen activities, suggesting their possible clinical application in
many diseases. Despite the advances that have been made in understanding the chemistry and biology of the anthraquinones in
recent years, research into their mechanisms of action and therapeutic potential in autoimmune disorders is still at an early stage.
In this paper, we briefly introduce the etiology of autoimmune diabetes, an autoimmune disorder that affects as many as 10 million
worldwide, and the role of chemotaxis in autoimmune diabetes.We then outline the chemical structure and biological properties of
the naturally occurring anthraquinones and their derivatives with an emphasis on recent findings about their immune regulation.
We discuss the structure and activity relationship, mode of action, and therapeutic potential of the anthraquinones in autoimmune
diabetes, including a new strategy for the use of the anthraquinones in autoimmune diabetes.
1. Autoimmune Diabetes
1.1. Etiology and Therapies for Autoimmune Diabetes.
Autoimmune diabetes (AID) is a life-threatening metabolic
disease that is initiated and progresses through a complex
interplay of environmental, genetic, and immune factors. As
a result, insulin-producing 𝛽-cells are destroyed by leuko-
cytes leading to insufficient/deficient insulin that fails to
maintain blood glucose homeostasis, and lethal macro- and
microvascular complications ensue. In 2013, the International
Diabetes Federation (IDF) estimated that some 79,000
children under 15 years develop AID annually worldwide [1].
In patients and animal models of AID, at disease onset,
leukocytes infiltrate into the pancreatic islets [2]. Among
the leukocytes, T lymphocytes are the main players in AID
although B lymphocytes, dendritic cells, macrophages, and
NK cells are also implicated in this invasion, a condition
termed insulitis [3, 4]. This invasion contributes to a gradual
loss of pancreatic 𝛽-cells, leading to insulin insufficiency/
deficiency and then hyperglycemia, two hallmarks of AID [5].
So far, insulin injection is the only way to control
AID; however, it fails to cure the disease and can only
ameliorate its complications. Therefore, discovery of novel
and effective approaches to cure AID is necessary. Immune
therapy, replacement therapy using insulin,𝛽-cells, islets, and
pancreas, and combination therapy have all been tested to
prevent and treat AID (Figure 1) [6]. Migration of leuko-
cytes during diabetes development is viewed as a critical
target through which to interfere with the disease onset and
progression. From the immune perspective, chemokines and
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Article ID 357357















(to inhibit immune cells)
Replacement therapy



















Figure 1: AID development and intervention. During AID onset, leukocytes start to invade pancreatic islets, a condition termed insulitis,
followed by diabetes. Diabetes is characterized by hyperglycemia, insulin insufficiency/deficiency, and glucosuria. Polydipsia, polyphagia,
and polyuria are found in diabetic patients. Diabetic complications such as retinopathy, nephropathy, foot ulcers, and cardiovascular disease
result in fatality of patients. Immunotherapy, replacement therapy, and combinations of both are common approaches to treat AID.
their pathways are attractive targets for intervention andmay
hold the key to stopping insulitis and, thus, delay or prevent
AID [7–10]. Preservation of functional 𝛽-cells is equally
crucial for curing AID [11]. This topic has been reviewed
elsewhere [12], however, and is not within the scope of this
paper.
1.2. Chemotaxis and Its Mechanism in Leukocytes. In mam-
mals, 23 chemokine receptors and over 50 chemokines have
been discovered (Figure 2) [13]. They function in health and
disease in roles such as cell recruitment during embryo-
genesis, leukocyte trafficking, helper T cell differentiation,
angiogenesis, HIV infection, sepsis, atherosclerosis, inflam-
mation, immune disorders, and cancer metastasis [14]. One
of the most important functions of chemokine/chemokine
receptors is to direct the migration of leukocytes from the
venous system to sites of inflammation.They play an essential
role in inflammation and, as a consequence, inflammatory
diseases such as autoimmune diseases and cancers [15]. Struc-
turally speaking, chemokine receptors belong to a family of 7-
helix transmembrane G protein-coupled receptors (GPCRs).
Upon chemokine engagement, chemokine receptors initiate
the binding of the G𝛼 subunit to guanosine triphosphate and
the dissociation of theG𝛼 subunit from theG𝛽𝛾 subunit.This
activates protein tyrosine kinases, mitogen-activated protein
(MAP) kinases, and phospholipase C. Secondarymessengers,
inositol triphosphate and diacylglycerol, which are converted
from phosphatidylinositol by phospholipase C, induce cel-
lular calcium influx and translocation/activation of protein
kinase C, respectively. The above biochemical cascades lead
to cell chemotaxis and other cell functions (Figure 4(a))
[16]. Hence, chemokines/chemokine receptors have been
proposed as drug targets for inflammatory diseases [14, 17–
19]. For instance, the first FDA approved CXCR4 antagonist,
plerixafor/AMD3100, is used to mobilize hematopoietic stem
cells, which are collected for use in stem cell graft in
patients with hematological cancers. Plerixafor was initially
developed to interfere with SDF-1/CXCR4 interaction and
shows promise for HIV infection, cancers, and autoimmune
diseases such as rheumatoid arthritis [20]. However, this drug
is expensive because of the difficulty in its total synthesis.
There is, therefore, a demand for the discovery of newCXCR4
antagonists that are both cost-effective and potent.
Since T cells and other leukocytes are thought to be
essential players in AID [3, 21], interference with chemokine
receptors in leukocytes could be a promising approach for
treating insulitis and AID prophylaxis. CXCR4 is expressed
in all the leukocytes including naı¨ve T cells [22]. CCR5 is
preferentially expressed in activated T cells and macrophages
[23–25]. And CCR3 and CCR4 are implicated in Th2 cells
whereas CXCR3 and CCR5 are associated with Th1 cells
[14]. On the flip side, genetic studies further showed that
deficiency in CXCR3 and CCR2 accelerated AID in NOD
mice [26, 27]. In contrast, CCR5 ablation delayed AID
[27], which was contradictory to one publication indicating




















































































Figure 2: Chemokines and their cognate receptors. Twenty-three chemokine receptors and their natural ligands are classified into CCR,
CXCR, and other categories.
that CCR5 positively regulated AID [28]. Anti-CXCL10 was
reported to delay AID in NOD mice, implying that CXCR3
may accelerate AID [29]. Overexpression of D6 in pancreatic
islets reduced AID in NOD mice [30]. Overexpression of
CCL2, a natural ligand for DARC, D6, and CCR2, in the
pancreas reduced AID in NODmice [31], which is consistent
with a negative regulation of AID by CCR2, D6, and DACR.
Of them, the impact of DARC in AID is unclear.
1.3. Mouse Models of AID. Animal models are indispensable
for dissecting pathogenesis and for preclinical trials in AID
despite some difference between animal models and patients.
The animal models include streptozotocin- (STZ-) treated
mice, nonobese diabetic (NOD) mice, Biobreeding (BB) rats,
Long Evans Tokushima Lean (LETL) rats, NewZealandwhite
rabbits, Chinese hamsters, Keeshond dogs, and Celebes black
apes [12].
2. Naturally Occurring Anthraquinones
2.1. Chemical Structure and Biosynthesis of Naturally Occur-
ring Anthraquinones. Naturally occurring anthraquinones
(NOAQs) are a group of secondary metabolites structurally
related to 9,10-dioxoanthracene (also known as anthracene
9,10-diones) and their glycosides (Table 1 and Figure 4). Cur-
rently, there are 79 known NOAQs [32], which were isolated









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Schema outlining the biosynthesis of anthraquinones. Anthraquinones can be synthesized from acetyl CoA and malonyl CoA via
the polyketide pathway (a), or from shikimic acid (b) via the shikimate pathway.
from lichens, fungi, or higher medicinal plants (e.g., Polyg-
onaceae, Rhamnaceae, Rubiaceae, Fabaceae, and Xanthor-
rhoeaceae) [32–38]. Although their biosynthetic pathways are
not yet fully clear, NOAQs can be biosynthesized from the
polyketide (Figure 3(a)) or shikimate (Figure 3(b)) pathway
as described in Figure 3 [39]. They can be formed either by
the cyclization of linear octa-𝛽-ketoacyl CoA intermediates
from the addition of one acetyl CoA to three malonyl CoA
or by the addition of succinoylbenzoic acid, resulting from
shikimic acid and𝛼-ketoglutaric acid, to mevalonic acid.
2.2. Mechanism of Action of NOAQs in AID. NOAQs have
widespread applications throughout medicine as well as in
industry. Medicinally speaking, they show a wide spectrum
of bioactivities. Most of them are best known as laxative
compounds for constipation. Apart from laxative activity,
emodin, the most studied anthraquinone, has been reported
to have cathartic, anti-inflammatory, anticancer, antimicro-
bial, diuretic, DNA-binding, and vasorelaxant activities [2,
55–57]. In addition, emodin, physcion, anthraglycoside B,
citreorosein, and emodin 8-O-𝛽-D-glucopyranoside were
found to have laxative, anti-inflammatory, and other activities
[58–60]. Emodin and physcion are kinase and tyrosinase
inhibitors [61–63] and also show cytotoxicity against can-
cer cells [55, 64]. In addition, emodin, citreorosein, and
emodin 8-O-𝛽-D-glucopyranoside showed phytoestrogen
activity [60, 65, 66]. Further, anthraglycoside B has been used
to treat acute hepatitis and leukocyte reduction [59].
Recently, NOAQs have been explored for their potential
in AID intervention. In one study, Fallopia japonica, an
anti-inflammatory herb rich in anthraquinones, was tested
for AID. NOD mice received intraperitoneal injection of the
F. japonica crude extract at 40 𝜇g/kg BW, 3 times a week from
4 to 30 weeks (prevention) or from 9 to 30 weeks (therapy).
Twelve-week-old NOD mice started to develop AID, and
100% of NODmice aged 24 weeks and above developed AID.
Remarkably, 86% and 80% of 30-week-old NODmice treated
with F. japonica crude extract did not develop AID [67].
Consistent withAID incidence, the crude extract delayed and
reduced the invasion of leukocytes into the pancreatic islets
[67]. Using a chemotaxis-based fractionation and isolation
approach, two anthraquinones, emodin and physcion, were
isolated and identified from this plant [67]. Moreover, in vitro
study showed that emodin and physcion exhibited a reduc-
tion in CXCR4-mediated migration of Jurkat cells, a human
T cell line [67]. A negative control, resveratrol, had no effect
on the CXCR4-implicated migration. This reduction in mi-
gration involved the inhibition of MAPKs, ERK 1/2, and
MAPKK, MEK 1/2 [67]. Accordingly, at doses from 4mg/kg
to 40mg/kg, emodin and physcion dose-dependently
reduced insulitis and AID in NODmice [67].
In another study, Shen and colleagues showed that
catenarin, cascarin, emodin, and rhein inhibited CXR4-
mediated chemotaxis in Jurkat T cells [28]. The half maximal
inhibitory concentrations (IC
50
) of the CXCR4-mediated
migration for catenarin, cascarin, emodin, and rhein were
0.18 𝜇g/mL, 0.3 𝜇g/mL, 0.3 𝜇g/mL, and 2.7 𝜇g/mL, respec-
tively [28]. The IC
50
of the CCR5-mediated migration for
catenarin, emodin, cascarin, and rhein were 0.5 𝜇g/mL,
0.75 𝜇g/mL, 1.46 𝜇g/mL, and 2.5 𝜇g/mL, respectively [28].






















Figure 4: Mode of action of catenarin and other anthraquinones for AID. (a) Upon chemokine binding, a chemokine receptor is activated
and induces G protein activation. A cascade of calcium mobilization and activation/phosphorylation of MAPKK/MAPK pathways leads
to chemotaxis of leukocytes and, subsequently, insulitis and diabetes. (b) Catenarin and probably other anthraquinones inhibit leukocyte
migration mediated by CCR5 and CXCR4 via the inactivation of MAPKs (p38 and JNK), MKKs (MKK6 and MKK7), and calcium
mobilization. As a result, anthraquinones can suppress insulitis and diabetes.
Catenarin had higher antichemotactic activity than the other
anthraquinones.This activity appears to relate to the number
of hydroxyl groups at R5 and R7 in the anthraquinones,
revealing a structure-activity relationship of hydroxyl groups
in anthraquinones. The 𝜇-slide assays, used to follow the
trafficking direction, also demonstrated that, at a dose of
0.5 𝜇g/mL, catenarin could completely stop cell movement
towards the specific chemokine gradient [28]. These data
suggest that the potential of the anthraquinones to inhibit
chemotaxis depends on chemokine properties [28]. Further,
in an in vivo study, 100% of NOD mice developed AID at
the age of 24 weeks or beyond. The diabetic incidence of
NOD mice treated with catenarin at 0.4, 4, and 20mg/kg,
3 times a week, from 4 to 30 weeks, was 80%, 70%, 30%,
and 0%. NOD mice treated with 20mg/kg catenarin had
normal blood glucose (<200mg/dL) andHb
𝐴1𝑐
(<4%), intact
islet structure, and very few leukocytes (CD4+ T, CD8+ T,
dendritic cells, macrophages, and NK and B cells) in the
pancreatic islets [28]. Flow cytometry showed that catenarin
did not influence the expression of chemokine receptors on
the cell surface, excluding the possibility that catenarin (and,
probably, other anthraquinones) work(s) at the level of the
chemokine receptors [28]. In addition, catenarin reduced
calcium mobilization in Jurkat cells whilst being exposed
to CXCR4 ligand, SDF-1, and CCR4 ligand, MIP-1 [28].
Further, catenarin inhibited JNK and p38 but not ERK
1/2 and, in turn, their upstream regulators, MKK 6/7 [28].
These mechanistic studies concluded that catenarin and/or
its derivatives exerted antidiabetic action via chemotactic
regulation of leukocytes involving the Ca2+/MAPKK/MAPK
pathways (Figure 4(b) and Table 2). Of note, catenarin has
the highest antichemotactic activity, followed in decreasing
order by emodin, cascarin, and rhein. Interestingly, catenarin
has two hydroxyl groups at R4 and R6 in its anthraquinone
ring. Emodin has only one hydroxyl group at R6. Cascarin
and rhein have no hydroxyl groups at R4 and R6.This activity
seems to be related to the number of hydroxyl groups at R4
and R6 in anthraquinones as described in Figure 4(a) and
Table 1.
Diacerein is a commercial drug commonly utilized to
treat human osteoarthritis. It was developed from its prodrug
rhein. Very interestingly, diacerein can be used to treat AID
inNODmice [68] akin to its prodrug, rhein [28]. Overall, the
data supported the notion that rhein in its stable form, albeit
at low efficacy, may be a better pharmaceutical intervention
than the other anthraquinones with higher activity.
There is lack of information about the impact of the
other chemokines/chemokine receptors in AID. We showed
that NOAQs can target CXCR4 and CCR5 pathways [28,
67]. CXCR3, CCR2, CXCL10, CCL2, and D6 were reported
Evidence-Based Complementary and Alternative Medicine 11
Table 2: NOAQs with antidiabetic activities.
S. number Name Classification Molecular formula Biological activities
72 Catenarin Anthraquinone C15H10O6 Antichemotactic [28] and antidiabetic [28]
69 Emodin Anthraquinone C15H10O5 Antichemotactic [67] and antidiabetic [67]
44 Physcion Anthraquinone C16H12O5 Antichemotactic [28]
70 Cascarin Anthraquinone C21H20O9 Antichemotactic [28]
71 Rhein Anthraquinone C15H8O6 Antichemotactic [28]
77 Diacerein Anthraquinone C19H12O8 Antiosteoarthritic [68] and antidiabetic [28]
to control diabetes development [26, 27, 29–31]. Whether
NOAQs target their pathways remains unclear.
3. Toxicology
Emodin, one of the most well-studied anthraquinones, is
frequently present in laxative herbs. Furthermore, emodin is
reported to be effective against cancer, constipation, inflam-
mation, microbes, and peptic ulcers [69]. However, its safety
and effectiveness in naturopathic treatment have not been
approved by the U.S. Food and Drug Administration (FDA).
Side effects of emodin, and probably other anthraquinones,
include potential carcinogenesis, nausea, diarrhea, and renal
failure. Two anthraquinone-type agents, danthron, a drug for
constipation, and diacerein, an anti-inflammatory drug for
osteoarthritis, were developed and approved by the U.S. FDA
[68, 70]. However, danthron was withdrawn by the FDA in
1999 due to the risk of carcinogenesis [70].Therefore, clinical
use of the anthraquinones should be considered cautiously.
4. Conclusions and Perspectives
Several NOAQs show anti-inflammatory activity. Among
them, cascarin, catenarin, rhein, physcion, and emodin sup-
press the chemotactic activity of leukocytes at the insuli-
tis stage of AID development. They suppress chemokine-
mediated leukocyte migration towards pancreatic islets lead-
ing to a decline in AID development. This suppression
involves anthraquinone-mediated inhibition of MAPKK/
MAPK pathway. An antiosteoarthritic anthraquinone drug,
diacerein, has been shown to prevent AID in a NOD model,
suggesting that the antichemotactic activity of the risk-free




NOAQ: Naturally occurring anthraquinone
NODmice: Nonobese diabetic mice
GPCR: G protein-coupled receptor
MAPK: Mitogen-activated protein kinase
MAPKK: Mitogen-activated protein kinase
IC
50
: Half maximal inhibitory concentration
STZ: Streptozotocin
BB rats: Biobreeding rats
LETL rats: Long Evans Tokushima Lean rats.
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